TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00698035

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Cream
Description: 1% micronized in velvachol - 0.5 gm of cream vaginally each night for two weeks, then 3 times a week for total of 12 weeks of treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estring
Description: 2mg ring inserted vaginally once every 12 weeks
Study: NCT04673604

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of ocular surface staining (Oxford score 0-15 scale)
Description: Corneal and conjunctiva staining will be recorded according to the Oxford grading scheme for ocular staining (0-15 score).

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Assessment of ocular surface staining (Oxford score 0-15 scale)
Description: Corneal and conjunctiva staining will be recorded according to the Oxford grading scheme for ocular staining (0-15 score).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mean diurnal intraocular pressure-lowering
Description: At the end of each 6-month period patients will undergo diurnal intraocular pressure assessment with both therapies.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: mean diurnal intraocular pressure-lowering
Description: At the end of each 6-month period patients will undergo diurnal intraocular pressure assessment with both therapies.
Study: NCT01824693

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic HCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic HCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given IV or PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO
Study: NCT02992834

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IL-2 pre-treated CD19 cells
Description: IL-2 stimulated, CD28-ζ-vector transfected T cells(TCRζ chimeric antigen receptor-T cell)， were administered at 1×106/kg by single infusion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IL-7/IL-15 pre-treated CD19 cells
Description: IL-7/IL-15 stimulated, CD28-ζ-vector transfected T cells(TCRζ chimeric antigen receptor-T cell)， were administered at 1×106/kg by single infusion
Study: NCT04403529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine Formulation
Description: The prescription for breast cancer Traditional Chinese Medicine formulation is a combination of 12 herbal components and it is available in granules form to be dissolved in hot water for consumption.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Formulation
Description: Placebo granules contains 5% prescription for breast cancer Traditional Chinese Medicine formulation and 95% filler, it is available in granules form to be dissolved in hot water for consumption.
Study: NCT06177119

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Description: SRP will be performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites will be scaled throughout the first week and treatment of the entire oral cavity will be completed in 14 days.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Description: SRP will be performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites will be scaled throughout the first week and treatment of the entire oral cavity will be completed in 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos during SRP
Description: Amoxicillin and metronidazole placebos thrice a day for 14 days, beginning with the first SRP session.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos after SRP
Description: Amoxicillin and metronidazole placebos thrice a day for 14 days, beginning after the last SRP session.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole during SRP
Description: Metronidazole 400 mg, thrice a day for 14 days, beginning with the first SRP session.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin during SRP
Description: Amoxicillin 500 mg, thrice a day for 14 days, beginning with the first SRP session.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole after SRP
Description: Metronidazole 400 mg, thrice a day for 14 days, beginning after the last SRP session.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin after SRP
Description: Amoxicillin 500 mg, thrice a day for 14 days, beginning after the last SRP session.
Study: NCT01691287

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Michael Method
Study: NCT04818528

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constraint Induced Movement Therapy and Routine Physical Therapy
Description: Intensive, graded practice of the paretic upper limb to enhance task-specific use of the affected limb. Constraint or forced use therapy, with the non-paretic upper limb contained in a mitt to promote the use of the impaired limb during 90% of the total hours awake. Adherence enhancing behavioral methods designed to transfer the gains obtained in the clinical setting or the laboratory to patients' real-world environment (ie, a transfer package).~As part of routine physical therapy patients received intervention that worked on aerobic capacity, muscle strengthening exercise, walking ability, postural and balance disorders and improving hand arm function. Three stages were used in each session: (i) warm-up phase: passive mobilization of major joints and lower limb muscle strengthening; (ii) active phase (both standing and sitting): motor control exercises for upper and lower limbs, and (iii) cool down phase (in seating position): respiratory exercises and mobilization.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Physical Therapy
Description: As part of routine physical therapy patients received intervention that worked on aerobic capacity, muscle strengthening exercise, walking ability, postural and balance disorders and improving hand arm function. Three stages were used in each session: (i) warm-up phase: passive mobilization of major joints and lower limb muscle strengthening; (ii) active phase (both standing and sitting): motor control exercises for upper and lower limbs, and (iii) cool down phase (in seating position): respiratory exercises and mobilization.
Study: NCT01677507

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Variation in eye pressure response to timolol and latanoprost treatment
Description: Arm 1 is to test for variation in eye pressure response to timolol. Arm 2 is to test for variation in eye pressure response to latanoprost.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Variation in eye pressure response to timolol and latanoprost treatment
Description: Arm 1 is to test for variation in eye pressure response to timolol. Arm 2 is to test for variation in eye pressure response to latanoprost.
Study: NCT04172311

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Atkins Diet
Description: Modified Atkins diet is a type of ketogenic diet which is less restrictive

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levetiracetam
Description: Levetiracetam is a second generation anti-epileptic drug which is broad spectrum and commonly used as add-on in refractory epilepsy
Study: NCT02452112

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% Lidocaine patch
Description: 5% Lidocaine patch to be placed on the site of pain

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo patch to be placed on the site of pain
Study: NCT03999541

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Freeze-all policy
Description: A policy of freezing all the embryos followed by subsequent thawed frozen embryo transfer
Study: NCT03409419

Intervention type: DRUG
Intervention: [18F] CFA
Description: pilot study to evaluate the bio-distribution of \[18F\] CFA, a new tracer for imaging the purine nucleoside biosynthetic pathway, before and after immunotherapy treatment in patients with metastatic or recurrent advanced melanoma.

Intervention type: DRUG
Intervention: [18F] CFA
Description: pilot study to evaluate the bio-distribution of \[18F\] CFA, a new tracer for imaging the purine nucleoside biosynthetic pathway, before and after immunotherapy treatment in patients with metastatic or recurrent advanced melanoma.
Study: NCT00515580

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tongue Sutures for Obstructive Sleep Apnea
Description: Mandibular osteotomy with placement of Silhouette sutures for genioglossus advancement and hyoid suspension.
Study: NCT04372342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nalbuphine
Description: Nalbuphine hydrochloride has strong analgesic effect, quick effect and long time by stimulating receptor, and has partial antagonistic effect on the receptor, so the incidence of respiratory depression is low in theory.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: remifentanil
Description: remifentanil
Study: NCT02802878

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid Training using Electrodes and Joint Motion Sensors
Description: Electrodes (Sekisui Plastics Co., Tokyo, Japan) will be placed on the anterior thigh over the motor points of the bilateral vastus medialis and lateralis, and on the posterior thigh over the motor points of the medial and lateral hamstrings. Electrical stimulation intensity will be set to approximately 40% of 1 repetition maximum (RM).~A joint motion sensor (Mutoh Engineering Inc., Tokyo, Japan) will trigger stimulation of the antagonist once it senses the initiation of volitional contraction of the agonist muscle group.
Study: NCT03217396

Intervention type: PROCEDURE
Intervention: lumbar puncture
Description: lumbar puncture performed to detect OCB for diagnostic purposes

Intervention type: PROCEDURE
Intervention: lumbar puncture
Description: lumbar puncture performed to detect OCB for diagnostic purposes

Intervention type: PROCEDURE
Intervention: lumbar puncture
Description: lumbar puncture performed to detect OCB for diagnostic purposes
Study: NCT02802878

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Isokinetic Training with Isokinetic Dynamometer
Description: Low intensity exercises completed using isokinetic dynamometer (HUMAC NORM, Computer Sports Medicine Inc. (CSMi), Stoughton, MA) in isokinetic mode at approximately 40%1 RM.
Study: NCT02665078

Intervention type: OTHER
Intervention: Thoracoscopic Ultrasound
Description: We will evaluate the resected specimen using the XLTF-UC180 in the operating room (OR) to determine the localization rate of the targets. Ultrasound measurement and images will be compared to the actual size of the tumor and pathological morphology using HE slides of lung tumor to determine the correlation between those variables. The tumor depth from the lung surface will be also collected to clarify the maximum depth to which the ultrasound can visualize.
Study: NCT03082053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varlitinib
Description: IMP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varlitinib
Description: IMP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Companion Medication
Study: NCT03261765

Intervention type: OTHER
Intervention: Assessment of adhesions
Description: Modified Nair scoring system

Intervention type: OTHER
Intervention: Assessment of adhesions
Description: Modified Nair scoring system
Study: NCT02302313

Intervention type: DEVICE
Group type: OTHER
Intervention: CO2 laser and ANI monitor
Description: Painful skin stimuli of variable intensity will be delivered by a CO2 laser used at the power of 0.3 W for each stimulation (6/phases) and this for each of the 3 phases (critical consciousness or hypnosis). During each stimulation, ANI values will be identified by the Physiodoloris ® monitor, through 3 standard ECG electrodes placed on the thorax of the subject.
Study: NCT02945800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: nab-Paclitaxel: 125 mg/m\^2 intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine: 1000 mg/m\^2 intravenously (IV)
Study: NCT04077736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: low dose interleukin-2 injected subcutaneously, at a dose of 1 million IU five days per week for 4 weeks (day1-5, 8-12, 15-19, 22-26) and then once a week for 8 weeks (day33, 40, 47, 54, 61, 68, 75, 82).
Study: NCT04624308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab 240mg d1，Q3W. Given with TPF during inductive chemotherapy and definitive radiotherapy.
Study: NCT00503425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab [MabThera/Rituxan]
Description: 1000 mg IV on days 1 and 15
Study: NCT04382027

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 + vitamin K2 (monoacylglycerol form)
Description: The intervention is a randomized double bond cross over design testing the pharmacokinetics of a monoglyceride formulation compared to an ethyl ester form.~Treatments are randomly assigned on days 0 and 7 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 9, 10, 12 and 24 hours. Each participant will perform the two treatments, with a minimum of 6 days between treatments.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 + vitamin K2 (ethyl ester)
Description: The intervention is a randomized double bond cross over design testing the pharmacokinetics of a monoglyceride formulation compared to an ethyl ester form.~Treatments are randomly assigned on days 0 and 7 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 9, 10, 12 and 24 hours. Each participant will perform the two treatments, with a minimum of 6 days between treatments.
Study: NCT02370472

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tool developed using cameras and a computer
Description: cameras allowing subject to be able to visualize hand and needle movements as well s the position of the transducers along with the image from the ultrasound on a computer screen
Study: NCT03116997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neostigmine+glycopyrrolate
Description: At the conclusion of surgery neuromuscular blockade reversed with neostigmine/glycopyrrolate
Study: NCT01686958

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR-Guided Transurethral US Ablation of Prostate Tissue
Description: The technology is developed to treat patients with organ confined prostate cancer. The therapeutic endpoint of this technology is thermal coagulation of prostate tissue.
Study: NCT02858973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Q203

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03116997

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: At the conclusion of surgery neuromuscular blockade reversed with sugammadex
Study: NCT01957787

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Application of extremely cold temperatures to the identified tumor(s).
Study: NCT01963754

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Implants in Posterior Mandible
Description: Place dental implants in posterior mandible, distal from canine, according to manufacturer recommendations
Study: NCT00613184

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nylon Flocked swab (Nasal secretion sampling)
Description: Nasal Aspirate Nylon Flocked swab

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nylon Flocked swab (Nasal secretion sampling)
Description: Nasal Aspirate Nylon Flocked swab
Study: NCT01963754

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental Implants in Posterior Mandible
Description: Place dental implants in posterior mandible, distal from canine, according to manufacturer recommendations
Study: NCT01963754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subperiosteal 1:100.000 Articaine 4% epinephrine
Description: Administration of subperiosteal anesthesia for implant placement
Study: NCT00613184

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nylon Flocked swab (Nasal secretion sampling)
Description: Nylon flocked swab Nasal Wash
Study: NCT02797314

Intervention type: OTHER
Group type: OTHER
Intervention: Bone biopsies
Description: Bone biopsies

Intervention type: OTHER
Group type: OTHER
Intervention: Bone biopsies
Description: Bone biopsies
Study: NCT05074225

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrodesiccation and Curettage vs Excision
Description: Factorial Assignment.~At the follow-up visit, two blinded observers will record their scores independently using the physician observer scar assessment score instrument (POSAS).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrodesiccation and Curettage vs Excision
Description: Factorial Assignment.~At the follow-up visit, two blinded observers will record their scores independently using the physician observer scar assessment score instrument (POSAS).
Study: NCT03435068

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ceramic rotary bur
Description: Gingivoplasties were performed with the same ceramic burs to easily provide a knife-edge appearance with ceramic rotary bur

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diode laser
Description: The fiber optic laser tip had a 320-μm diameter with a 2.8 W output power were used in the study.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Scalpel
Description: Scalpel surgery were performed as control group (conventioanl group).
Study: NCT01816048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-700
Description: TAK-700 will be administered at 300mg twice per day on 28-day continuous cycles
Study: NCT00251719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR
Description: Dexlansoprazole MR 60 mg, capsules, orally, once daily (QD) for up to 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR
Description: Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
Study: NCT01270737

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whole soy (soy flour)
Description: 40g soy flour per day for six months
Study: NCT01816048

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fluorine F 18 Sodium Fluoride
Description: Undergo NaF F18 PET/CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo 18F NaF PET/CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo 18F NaF PET/CT scan
Study: NCT01270737

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: daidzein
Description: 66mg daidzein per day for six months
Study: NCT04314817

Intervention type: DRUG
Intervention: Any drug used to treat Covid-19
Description: lopinavir/ritonavir, remdesivir, interferon beta-1a, chloroquine and/or azithromycin. This list may be amended at a further date.
Study: NCT05002348

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser acupoint stimulation(Laser pen)
Description: Select 5-7 acupuncture points according to physical fitness. Each acupoint is performed once a day. The acupuncture point stimulation process takes about 3-5 minutes. The patient wears goggles and observes the patient's vital signs (blood pressure, heartbeat and blood oxygen) with a physiological monitor. , If the patient has any discomfort, the procedure will be stopped for a maximum of 10 days.
Study: NCT03288844

Intervention type: PROCEDURE
Intervention: Ophthalmologic examinations
Description: epithelial defects assessment by fluorescein staining; superficial corneal neo-vascularization assessment; ocular tonometry; slit lamp examination; conjunctival (both bulbar and limbal) inflammation assessment; corneal sensitivity; central cornea involvement (for opacity or central CNV); Best-Corrected Visual Acuity; evaluation of symptoms.

Intervention type: OTHER
Intervention: Digital pictures
Description: Digital pictures 2D to be taken at each visit
Study: NCT01270737

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: milk powder
Description: 40g low-fat dry milk per day for six months
Study: NCT03288844

Intervention type: OTHER
Intervention: QoL Questionnaires
Description: Quality of Life (NEI VFQ 25 and EQ-5D-3L/Y) questionnaires will be submitted at each visit
Study: NCT01949129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VP16
Description: 60 mg/kg BW,1 day in TBI/VP16 conditioning; 40 mg/kg BW in Bu/VP16/Cy conditioning

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VP16
Description: 60 mg/kg BW,1 day in TBI/VP16 conditioning; 40 mg/kg BW in Bu/VP16/Cy conditioning

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: TBI
Description: 2 x 2Gy/day , 3 days (total 12Gy)
Study: NCT01963754

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loco-regional 1:100.000 Articaine 4% epinephrine
Description: Administer loco-regional anesthesia for implant placement in posterior mandible
Study: NCT01949129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: 2x5 mg/kg BW, 1 day